Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Glioma × ivosidenib × Clear all

Phase

Status

Sponsor Class

NIH 2 OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 8 Recurrence 2 Leukemia 2 Cholangiocarcinoma 2 Neoplasms, Unknown Primary 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 IDH1-Mutated Malignancies 1 Hematologic Neoplasms 1 Glioma 1

Interventions

Temozolomide 28 Bevacizumab 10 Radiotherapy 9 Surgical Procedures, Operative 6 Lomustine 6 IL13-PE38 6 Carboplatin 6 TIC10 compound 5 vorasidenib 4 trametinib 4 dabrafenib 4 Flucytosine 4 Dianhydrogalactitol 4 Chlorotoxin 4 vocimagene amiretrorepvec 3 Radiation 3 Paclitaxel 3 OKN 007 3 Irinotecan 3 Granulocyte-Macrophage Colony-Stimulating Factor 3 Cyclophosphamide 3 CLR1404 3 trans-sodium crocetinate 2 pembrolizumab 2 marizomib 2 lenvatinib 2 enzastaurin 2 contrast agent BR1 2 avapritinib 2 abemaciclib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03343197 2026-02-17

Study of AG-120 and AG-881 in Subjects With Low Grade Glioma

Servier

Phase 1 Completed

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡